11/13
02:43 pm
iron
Disc Medicine, Inc. (NASDAQ: IRON) had its price target raised by analysts at HC Wainwright from $70.00 to $118.00. They now have a "buy" rating on the stock.
Low
Report
Disc Medicine, Inc. (NASDAQ: IRON) had its price target raised by analysts at HC Wainwright from $70.00 to $118.00. They now have a "buy" rating on the stock.
11/13
08:30 am
iron
Disc Medicine to Participate in Upcoming Investor Conferences
Low
Report
Disc Medicine to Participate in Upcoming Investor Conferences
11/13
12:45 am
iron
Disc Medicine, Inc. (NASDAQ: IRON) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $83.00 price target on the stock, up previously from $75.00.
Low
Report
Disc Medicine, Inc. (NASDAQ: IRON) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $83.00 price target on the stock, up previously from $75.00.
11/12
08:00 am
iron
Disc Medicine Reports Third Quarter 2024 Financial Results and Provides Business Update
Medium
Report
Disc Medicine Reports Third Quarter 2024 Financial Results and Provides Business Update
11/8
08:34 am
iron
Disc Medicine Secures $200 Million in Non-Dilutive Debt Financing from Hercules Capital, Inc. [Yahoo! Finance]
Low
Report
Disc Medicine Secures $200 Million in Non-Dilutive Debt Financing from Hercules Capital, Inc. [Yahoo! Finance]
11/8
08:30 am
iron
Disc Medicine Secures $200 Million in Non-Dilutive Debt Financing from Hercules Capital, Inc.
Neutral
Report
Disc Medicine Secures $200 Million in Non-Dilutive Debt Financing from Hercules Capital, Inc.
11/5
07:44 pm
iron
Disc Medicine, Inc. (NASDAQ: IRON) had its price target raised by analysts at Scotiabank from $62.00 to $70.00. They now have a "sector outperform" rating on the stock.
Low
Report
Disc Medicine, Inc. (NASDAQ: IRON) had its price target raised by analysts at Scotiabank from $62.00 to $70.00. They now have a "sector outperform" rating on the stock.
11/5
09:43 am
iron
Disc Medicine, Inc. (NASDAQ: IRON) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $70.00 price target on the stock.
High
Report
Disc Medicine, Inc. (NASDAQ: IRON) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $70.00 price target on the stock.
11/5
09:00 am
iron
Disc Medicine Announces Multiple Presentations Across Portfolio at the 66th American Society of Hematology (ASH) Annual Meeting
Medium
Report
Disc Medicine Announces Multiple Presentations Across Portfolio at the 66th American Society of Hematology (ASH) Annual Meeting
11/5
07:30 am
iron
Disc Medicine, Inc. (NASDAQ: IRON) was upgraded by analysts at Morgan Stanley from an "equal weight" rating to an "overweight" rating. They now have a $85.00 price target on the stock.
High
Report
Disc Medicine, Inc. (NASDAQ: IRON) was upgraded by analysts at Morgan Stanley from an "equal weight" rating to an "overweight" rating. They now have a $85.00 price target on the stock.
11/4
10:47 pm
iron
Disc Medicine, Inc. (NASDAQ: IRON) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $75.00 price target on the stock, up previously from $60.00.
Medium
Report
Disc Medicine, Inc. (NASDAQ: IRON) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $75.00 price target on the stock, up previously from $60.00.
11/4
09:42 am
iron
Disc Medicine, Inc. (NASDAQ: IRON) was upgraded by analysts at Raymond James from an "outperform" rating to a "strong-buy" rating. They now have a $110.00 price target on the stock, up previously from $66.00.
Low
Report
Disc Medicine, Inc. (NASDAQ: IRON) was upgraded by analysts at Raymond James from an "outperform" rating to a "strong-buy" rating. They now have a $110.00 price target on the stock, up previously from $66.00.
11/4
07:59 am
iron
Disc Medicine Announces Successful End of Phase 2 Meeting with FDA for Bitopertin in Erythropoietic Protoporphyria (EPP), Including Potential for Accelerated Approval [Yahoo! Finance]
High
Report
Disc Medicine Announces Successful End of Phase 2 Meeting with FDA for Bitopertin in Erythropoietic Protoporphyria (EPP), Including Potential for Accelerated Approval [Yahoo! Finance]
11/4
07:50 am
iron
Disc Medicine Announces Successful End of Phase 2 Meeting with FDA for Bitopertin in Erythropoietic Protoporphyria (EPP), Including Potential for Accelerated Approval
High
Report
Disc Medicine Announces Successful End of Phase 2 Meeting with FDA for Bitopertin in Erythropoietic Protoporphyria (EPP), Including Potential for Accelerated Approval
11/1
04:01 pm
iron
Disc Medicine to Host Conference Call on End of Phase 2 FDA Meeting for Bitopertin in Erythropoietic Protoporphyria (EPP)
High
Report
Disc Medicine to Host Conference Call on End of Phase 2 FDA Meeting for Bitopertin in Erythropoietic Protoporphyria (EPP)
10/28
08:25 am
iron
Disc Medicine, Inc. (NASDAQ: IRON) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $70.00 price target on the stock.
Low
Report
Disc Medicine, Inc. (NASDAQ: IRON) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $70.00 price target on the stock.
10/25
01:06 pm
iron
Disc Medicine Presents Positive Data from SAD Cohorts of a Phase 1b Trial in Patients with Chronic Kidney Disease (CKD) and Anemia at the 2024 American Society of Nephrology (ASN) Kidney Week [Yahoo! Finance]
Medium
Report
Disc Medicine Presents Positive Data from SAD Cohorts of a Phase 1b Trial in Patients with Chronic Kidney Disease (CKD) and Anemia at the 2024 American Society of Nephrology (ASN) Kidney Week [Yahoo! Finance]
10/25
01:00 pm
iron
Disc Medicine Presents Positive Data from SAD Cohorts of a Phase 1b Trial in Patients with Chronic Kidney Disease (CKD) and Anemia at the 2024 American Society of Nephrology (ASN) Kidney Week
Low
Report
Disc Medicine Presents Positive Data from SAD Cohorts of a Phase 1b Trial in Patients with Chronic Kidney Disease (CKD) and Anemia at the 2024 American Society of Nephrology (ASN) Kidney Week
10/23
08:45 am
iron
Disc Medicine appoints Rahul Kaushik as chief technology officer [Seeking Alpha]
High
Report
Disc Medicine appoints Rahul Kaushik as chief technology officer [Seeking Alpha]
10/23
08:00 am
iron
Disc Medicine Appoints Seasoned Industry Executive Rahul Kaushik, Ph.D. as Chief Technical Officer
Medium
Report
Disc Medicine Appoints Seasoned Industry Executive Rahul Kaushik, Ph.D. as Chief Technical Officer
10/23
07:35 am
iron
Disc Medicine, Inc. (NASDAQ: IRON) is now covered by analysts at Jefferies Financial Group Inc.. They set a "buy" rating and a $89.00 price target on the stock.
Medium
Report
Disc Medicine, Inc. (NASDAQ: IRON) is now covered by analysts at Jefferies Financial Group Inc.. They set a "buy" rating and a $89.00 price target on the stock.
10/16
08:44 am
iron
Disc Medicine, Inc. (NASDAQ: IRON) is now covered by analysts at Scotiabank. They set a "sector outperform" rating on the stock.
Low
Report
Disc Medicine, Inc. (NASDAQ: IRON) is now covered by analysts at Scotiabank. They set a "sector outperform" rating on the stock.
10/15
11:10 am
iron
Disc Medicine, Inc. (NASDAQ: IRON) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $85.00 price target on the stock.
Low
Report
Disc Medicine, Inc. (NASDAQ: IRON) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $85.00 price target on the stock.
10/11
08:00 am
iron
Disc Medicine Announces Presentation of New Data from Phase 1b Trial of DISC-0974 in Patients with Chronic Kidney Disease (CKD) and Anemia at 2024 American Society of Nephrology (ASN) Kidney Week
Low
Report
Disc Medicine Announces Presentation of New Data from Phase 1b Trial of DISC-0974 in Patients with Chronic Kidney Disease (CKD) and Anemia at 2024 American Society of Nephrology (ASN) Kidney Week
10/6
08:34 am
iron
Disc Medicine: Achieving Functional Endpoint More Important [Seeking Alpha]
Medium
Report
Disc Medicine: Achieving Functional Endpoint More Important [Seeking Alpha]